Musashi 2影响慢性淋巴细胞白血病细胞存活与生长,成为潜在治疗靶点
该研究比较CLL近期分裂与既往分裂细胞的基因表达,发现MSI2在分裂及近期分裂的白血病细胞中蛋白水平更高。下调或阻断MSI2可清除原代人和鼠CLL及成熟髓系细胞,而不影响成熟T细胞和造血干祖细胞。高MSI2水平与不良预后标志、较短至首次治疗时间和总生存相关。
要点
- MSI2蛋白在分裂及近期分裂的CLL细胞中水平更高。
- 下调或阻断MSI2可清除原代人和鼠CLL及成熟髓系细胞。
- 高MSI2水平与不良预后标志、较短至首次治疗时间和总生存相关。
核心结论
- MSI2在CLL细胞存活和增殖中起重要作用,并与CLL患者不良预后相关,是潜在治疗靶点。
研究设计与样本
- 研究比较了近期分裂与既往分裂CLL细胞的全局基因表达,并开展离体和体外实验。
主要发现
- MSI2蛋白水平在分裂和近期分裂的白血病细胞中更高。
- 下调MSI2表达或阻断其功能可清除原代人和鼠CLL及成熟髓系细胞。
- 成熟T细胞和造血干祖细胞不受影响。
- 较高MSI2水平与不良预后标志、较短至首次治疗时间和总生存相关。
临床怎么用
- MSI2可能作为CLL的潜在治疗靶点,但尚需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Progression of chronic lymphocytic leukemia (CLL) results from the expansion of a small fraction of proliferating leukemic B cells. When comparing the global gene expression of recently divided CLL cells with that of previously divided cells, we found higher levels of genes involved in regulating gene expression. One of these was the oncogene Musashi 2 (MSI2), an RNA-binding protein that induces or represses translation. While there is an established role for MSI2 in normal and malignant stem cells, much less is known about its expression and role in CLL. Here we report for the first time ex vivo and in vitro experiments that MSI2 protein levels are higher in dividing and recently divided leukemic cells and that downregulating MSI2 expression or blocking its function eliminates primary human and murine CLL and mature myeloid cells. Notably, mature T cells and hematopoietic stem and progenitor cells are not affected. We also confirm that higher MSI2 levels correlate with poor outcome markers, shorter time-to-first-treatment, and overall survival. Thus, our data highlight an important role for MSI2 in CLL-cell survival and proliferation and associate MSI2 with poor prognosis in CLL patients. Collectively, these findings pinpoint MSI2 as a potentially valuable therapeutic target in CLL.
引用
- Palacios F, Yan XJ, Ferrer G, et al. Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. Leukemia. 2021. PMID: 33504942. doi:10.1038/s41375-020-01115-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。